Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.

The Journal of biological chemistry - 1 Jun 2023

Juliana Christine A, Chai Jinghua, Arroyo Pablo, Rico-Bautista Elizabeth, Betz Stephen F, De León Diva D

Abstract excerpt

Congenital hyperinsulinism (HI), a beta cell disorder most commonly caused by inactivating mutations of beta cell KATP channels, results in dysregulated insulin secretion and persistent hypoglycemia. Children with KATP-HI are unresponsive to diazoxide, the only FDA-approved drug for HI, and utility of octreotide, the second-line therapy, is limited because of poor efficacy, desensitization, and somatostatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Amino Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperinsulinism

Share to Hypoglycemia

Share to Insulin Secretion

Share to Islets of Langerhans

Share to Potassium Channels, Inwardly Rectifying

Share to Receptors, Somatomedin

Source

Open in PubMed Open full text

Identifiers

PMID: 37178920
DOI: 10.1016/j.jbc.2023.104816
PMCID: PMC10318504

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.PMID 37178920Read ↗

GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.Semantic proximity Read ↗

KATP channel mutations in congenital hyperinsulinism: Progress and challenges towards mechanism-based therapies.Semantic proximity Read ↗

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.Semantic proximity Read ↗

SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism.Semantic proximity Read ↗

Hyperinsulinism of infancy: the regulated release of insulin by KATP channel-independent pathways.Semantic proximity Read ↗

Persistent hyperinsulinemic hypoglycemia of infancy.Semantic proximity Read ↗

Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose.Semantic proximity Read ↗

Sur1 Knockout MiceSemantic proximity Read ↗

Acute D-Serine Co-Agonism of β-Cell NMDA Receptors Potentiates Glucose-Stimulated Insulin Secretion and Excitatory β-Cell Membrane Activity.Semantic proximity Read ↗

Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations.Semantic proximity Read ↗

Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.Semantic proximity Read ↗

Hyperinsulinism in infancy and childhood: when an insulin level is not always enough.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.